Synthesis and evaluation of the targeted binding of RGD-containing PEGylated-PEI/DNA polyplex micelles as radiotracers for a tumor-targeting imaging probe

RSC Advances ◽  
2015 ◽  
Vol 5 (130) ◽  
pp. 107455-107465 ◽  
Author(s):  
Adhimoorthy Prasannan ◽  
Tilahun Ayane Debele ◽  
Hsieh-Chih Tsai ◽  
Chiz-Cheng Chao ◽  
Che-Ping Lin ◽  
...  

Polyplex micelles with pEGFP and RGD-modified poly(ethylene glycol)-grafted polyethylenimine (E[c(RGDyK)]2-PEG-g-PEI) and were labeled with 99mTc for the in vivo study as proficient probes for molecular imaging.

2004 ◽  
Vol 845 ◽  
Author(s):  
Goldie Kaul ◽  
Mansoor Amiji

ABSTRACTIn order to develop a safe and effective systemically-administered delivery system for solid tumors, the biodistribution of control gelatin and poly(ethylene-glycol) modified (PEGylated) gelatin nanoparticles was examined in Lewis lung carcinoma (LLC)-bearing female C57BL6 mice. Type B gelatin and PEGylated gelatin nanoparticles were radiolabeled (125I) for the in vivo biodistribution studies after intravenous (i.v.) administration through the tail vein in LLC-bearing mice. At various time intervals, the tumor-bearing mice were sacrificed and tumor, blood, and major organs were harvested for analysis of radioactivity corresponding to the localization of the nanoparticles. Percent recovered dose was determined and normalized to the weight of the tissue or fluid sample. Non-compartmental pharmacokinetic analysis was performed to determine the long-circulating property and preferential tumor targeting potential of PEGylated gelatin nanoparticles in vivo. From the radioactivity in plasma and various organs collected, it was evident that the majority of PEGylated nanoparticles were present either in the blood pool or taken up by the tumor mass and liver. For instance, after 3 hours, the PEGylated gelatin nanoparticles were almost 2-fold higher in the blood pool than the control gelatin nanoparticles. PEGylated gelatin nanoparticles remained in the blood pool for a longer period of time due to the steric repulsion effect of the PEG chains as compared to the control gelatin nanoparticles. In addition, approximately 4-5% of the recovered dose of PEGylated gelatin nanoparticles was present in the tumor mass for up to 12 hours. The plasma and the tumor half-lives, area-under-the-curve, and the mean residence time of the PEGylated gelatin nanoparticles were significantly greater than those of the control gelatin nanoparticles. The results of the study confirmed long-circulating property and preferential tumor targeting potential of PEGylated gelatin nanoparticles in a murine tumor model.


RSC Advances ◽  
2016 ◽  
Vol 6 (113) ◽  
pp. 112552-112561 ◽  
Author(s):  
Lin Lin ◽  
Jie Chen ◽  
Zhaopei Guo ◽  
Wantong Song ◽  
Dawei Zhang ◽  
...  

To improve the abilities of long-term circulation and tumor targeting, poly(ethylene glycol) modified polyethylenimine with or without RGD peptide ligands were synthesized and evaluated in detail.


Molecules ◽  
2021 ◽  
Vol 26 (5) ◽  
pp. 1438
Author(s):  
Silvio Curia ◽  
Feifei Ng ◽  
Marie-Emérentienne Cagnon ◽  
Victor Nicoulin ◽  
Adolfo Lopez-Noriega

This article presents the evaluation of diblock and triblock poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) amphiphilic copolymers (PEG-PTMCs) as excipients for the formulation of long-acting injectables (LAIs). Copolymers were successfully synthesised through bulk ring-opening polymerisation. The concomitant formation of PTMC homopolymer could not be avoided irrespective of the catalyst amount, but the by-product could easily be removed by gel chromatography. Pure PEG-PTMCs undergo faster erosion in vivo than their corresponding homopolymer. Furthermore, these copolymers show outstanding stability compared to their polyester analogues when formulated with amine-containing reactive drugs, which makes them particularly suitable as LAIs for the sustained release of drugs susceptible to acylation.


2018 ◽  
Vol 47 (3) ◽  
pp. 426-432 ◽  
Author(s):  
Sivan Yogev ◽  
Ayelet Shabtay-Orbach ◽  
Abraham Nyska ◽  
Boaz Mizrahi

Thermoresponsive materials have the ability to respond to a small change in temperature—a property that makes them useful in a wide range of applications and medical devices. Although very promising, there is only little conclusive data about the cytotoxicity and tissue toxicity of these materials. This work studied the biocompatibility of three Food and Drug Administration approved thermoresponsive polymers: poly( N-isopropyl acrylamide), poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) tri-block copolymer, and poly(lactic acid-co-glycolic acid) and poly(ethylene glycol) tri-block copolymer. Fibroblast NIH 3T3 and HaCaT keratinocyte cells were used for the cytotoxicity testing and a mouse model for the in vivo evaluation. In vivo results generally showed similar trends as the results seen in vitro, with all tested materials presenting a satisfactory biocompatibility in vivo. pNIPAM, however, showed the highest toxicity both in vitro and in vivo, which was explained by the release of harmful monomers and impurities. More data focusing on the biocompatibility of novel thermoresponsive biomaterials will facilitate the use of existing and future medical devices.


Biomaterials ◽  
2004 ◽  
Vol 25 (2) ◽  
pp. 247-258 ◽  
Author(s):  
A.A. Deschamps ◽  
A.A. van Apeldoorn ◽  
H. Hayen ◽  
J.D. de Bruijn ◽  
U. Karst ◽  
...  

2007 ◽  
Vol 341 (1-2) ◽  
pp. 50-57 ◽  
Author(s):  
Hoo-Kyun Choi ◽  
Myung-Kwan Chun ◽  
Se Hee Lee ◽  
Mee Hee Jang ◽  
Hee Doo Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document